Integrative Analysis Of The Genomic And Transcriptomic Landscape Of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax In Combination With Bortezomib And Dexamethasone: Biomarker Analyses From The Phase 3 Bellini Study

Background: Multiple myeloma (MM) is a clonal plasma cell malignancy characterized by a complex genomic landscape with molecular and clinical heterogeneity. Venetoclax (Ven) is a selective, potent, oral BCL-2 inhibitor currently under investigation as a potential targeted therapy for the treatment of relapsed/refractory (RR) MM. Using a next-generation sequencing (NGS)-based approach, the mutational landscape and gene expression profile (GEP) of patients (pts) with RRMM in BELLINI was evaluated for potential impact on observed clinical outcomes in key biomarker subgroups.